1,075 reports of this reaction
3.6% of all RALTEGRAVIR reports
#2 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #2 most commonly reported adverse reaction for RALTEGRAVIR, manufactured by Merck Sharp & Dohme LLC. There are 1,075 FDA adverse event reports linking RALTEGRAVIR to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 3.6% of all 29,953 adverse event reports for this drug.
Patients taking RALTEGRAVIR who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is moderately reported among RALTEGRAVIR users, representing a notable but not dominant share of adverse events.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for RALTEGRAVIR:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 1,075 FDA reports for RALTEGRAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 3.6% of all adverse event reports for RALTEGRAVIR, making it one of the most commonly reported side effect.
If you experience foetal exposure during pregnancy while taking RALTEGRAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.